Unstable angina - A definitive role for statins in secondary prevention

International Journal of Clinical Practice

Volumn 54, Issue 6, 2000, Pages 383-389

  Colquhoun, D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PRAVASTATIN; STATIN;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; DRUG TOLERANCE; FEMALE; HUMANS; MALE; PRAVASTATIN; RECURRENCE;

EID: 0033867368     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Gyongyosi M, Yang P, Hassan A et al. Coronary risk factors influence plaque morphology in patients with unstable angina. Coron Artery Dis 1999; 10: 211-219.
2. Chierchia S. Current therapeutic strategies in unstable angina. Eur Heart J 1999; 1(suppl N): 2-6.
3. Fox KA, Cokkinos DV, Deckers JW et al. Current management of unstable angina in Europe (abstract). J Am Coll Cardiol 2000; 35(suppl A): 352.
4. Cairns J, Theroux P, Armstrong P et al. Unstable angina: report from a Canadian expert roundtable. Can J Cardiol 1996; 12: 1279-1292.
5. Braunwald E, Jones RH, Mark DB et al. Diagnosing and managing unstable angina. Agency for Health Care Policy and Research. Circulation 1994; 90: 613-622.
6. Graves E. National Hospital Discharge Survey: annual survey 1996. National Centre for Health Statistics, Washington DC 1998; Series 13, no 4.
7. Hilton TC, Chaitman BR. The prognosis in stable and unstable angina. Cardiol Clin 1991; 9: 27-38.
8. Seres GL, Valle TV. Current prognosis of unstable angina. The results of clinical studies. Rev Esp Cardiol 1999; 52(suppl 1): 61-66.
9. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-2020.
10. Little WC, Constantinescu M, Applegate RJ et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78: 1157-1166.
11. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850.
12. Crea F, Biasucci LM, Buffon A et al. Role of inflammation in the pathogenesis of unstable coronary artery disease. Am J Cardiol 1997; 80: 10E-16E.
13. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223-1230.
14. Hansson, GK, Libby P. The role of the lymphocyte. In: Fuster V, Ross R, Topol EJ, Eds. Atherosclerosis and coronary artery disease, 1st edn. Philadelphia: Lippincott-Raven, 1996; 557-568.
15. Geng YJ, Wu Q, Muszynski M et al. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 1996; 16: 19-27.
16. Boyle JJ, Bennett MR, Proudfoot D et al. Human monocyte/macrophages induce human vascular smooth muscle apoptosis in culture (abstract). J Pathol 1998; 184: 13.
17. Bennett MR, Macdonald K, Chan SW et al. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ Res 1998; 82: 704-712.
18. Bennett MR, Boyle JJ. Apoptosis of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 1998; 138: 3-9.
19. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
20. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; ii: 941-944.
21. Cheng GC, Loree HM, Kamm RD et al. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathological correlation. Circulation 1993; 87: 1179-1187.
22. Galis ZS, Sukhova GK, Kranzhofer R et al. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92: 402-406.
23. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999; 82: 265-268.
24. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97: 1195-1206.
25. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med 2000; 342: 101-114.
26. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
27. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
28. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
29. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
30. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
31. Arntz HR, Wunderlich W, Schnitzer L. The decisive importance of cholesterol lowering therapy for coronary lesions and clinical course immediately after an acute coronary event: short and long term results of a a controlled study (abstract). Circulation 1998; 98: 222.
32. Mainard F, Ozanne P, Madec Y. Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction. Atherosclerosis 1988; 69: 225-231.
33. MBewu AD, Durrington PN, Bulleid S, Mackness MI. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis 1993; 103: 65-71.
34. Pfohl M, Schreiber I, Liebich HM et al. Upregulation of cholesterol synthesis after acute myocardial infarction: is cholesterol a positive acute phase reactant? Atherosclerosis 1999; 142: 389-393.
35. Goldstein MF. Should reductase inhibitor therapy to lower cholesterol be instituted in the setting of an acute coronary event? (letter). Atherosclerosis 2000; 149: 215-216.
36. Kayikcioglu M, Turkoglu C, Kultursay H et al. The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction (abstract). Circulation 1999; 100: 1586.
37. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-3233.
38. den Hartog F, Verbeugt F. Early HMG-COA reductase inhibition in acute coronary syndromes: preliminary data of the pravastatin in acute ischaemic syndromes study (PAIS) (abstract). Eur Heart J 1998; 19: 2802.
39. Kesteloot H, Claeys G, Blanckaert N, Lesaffre E. Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin. Acta Cardiol 1997; 52: 107-116.
40. Aronow HD, Roe TM, Lauer MS et al. Early and striking mortality reduction after acute coronary syndromes following lipid lowering therapy (abstract). J Am Coll Cardiol 2000; 35: 411.
41. Bybee KA, Wright RS, Williams BA et al. Is use of a statin agent at the time of presentation for acute myocardial infarction associated with a favorable outcome? (abstract). J Am Coll Cardiol 2000; 35: 314.
42. Schwartz GG, Oliver MF, Ezekowitz MD et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study that evaluates atorvastin in unstable angina pectoris and in non-Q-wave myocardial infarction. Am J Cardiol 1998; 81: 578-581.
43. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. Am J Cardiol 1997; 79: 756-762.
44. Arntz HR. Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events. Atherosclerosis 1999; 147(suppl 1): S17-S21.
45. Todd IC, Wosornu D, Stewart I, Wild T. Cardiac rehabilitation following myocardial infarction: a practical approach. Sports Med 1992; 14: 243-259.
46. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997; 18: 1718-1724.
47. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol Lancet 1996; 348: 1079-1082. [erratum Lancet 1997; 349: 214]
48. Rosenson R, Tangney C. Antiatherothrombotic properties of statins implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
49. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999; 10: 543-559.
50. Vaughan CJ, Gotto AM, Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10.
51. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
52. Treasure CB, Manoukian SV, Klein JL et al. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res 1992; 71: 776-781.
53. Cooke JP, Tsao PS. Is NO an endogenous antiatherogenic molecule? (editorial; comment). Arterioscler Thromb 1994; 14: 653-655.
54. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
55. Celermajer D. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997; 30: 325-333.
56. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-241.
57. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-691.
58. Crisby M, Shah PK, Yano J et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, matrix metalloproteinases and cell death in human carotid plaques favouring lesion stability (abstract). Circulation 1999; 100: 469.
59. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-1445.
60. Lacoste L, Lam JY, Hung J et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-3177.
61. Lacoste L, Lam JY. Comparative effect of paravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients (abstract). J Am Coll Cardiol 1996; 27: 413.
62. Davi G, Averna M, Novo S et al. Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. Atherosclerosis 1989; 79: 79-83.
63. Tsuda Y, Satoh K, Kitadai M et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225-233.
64. Bo M, Bonino F, Neirotti M et al. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991; 42: 106-113.
65. Dangas G, Ambrose J, Smith D et al. Treatment of hyperlipidaemia with pravastatin improves the systemic haemostatic/fibrinolytic profile and decreases thrombus formation (abstract). Eur Heart J 1998; 19: 808.
66. Avellone G, DiGarbo v, Cordova R et al. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipo-proteinemia. Curr Ther Res Clin Exp 1994; 55: 1335-1344.
67. Mitropoulos KA, Armitage JM, Collins R et al. Randomized placebocontrolled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group. Eur Heart J 1997; 18: 235-241.
68. Davidson M, McKenney J, Stein E et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 1997; 79: 1475-1481.
69. Negre-Aminou P, van Vliet AK, van Erck M et al. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997; 1345: 259-268.
70. Corsini A, Raiteri M, Soma M et al. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 1991; 23: 173-180.
71. Soma MR, Donetti E, Parolini C et al. HMG CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993; 13: 571-578.
72. Alfon J, Guasch JF, Berrozpe M, Badimon L. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening: preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis 1999; 145: 325-331.
73. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Safety 1996; 14: 11-24.
74. Bottorff M. 'Fire and forget?' - pharmacological considerations in coronary care. Atherosclerosis 1999; 147(suppl 1): S23-S30.
75. Horsmans Y, Desager JP, van den Berge V et al. Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol Res 1993; 28: 243-248.
76. Ahmad S. Diltiazem myopathy (letter). Am Heart J 1993; 126: 1494-1495.
77. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397-402.
78. Weissberg P. Mechanisms modifying atherosclerotic disease. Atherosclerosis 1999; 147(suppl 1): S3-S10.
79. Aengevaeren WR. Beyond lipids: the role of the endothelium in coronary artery disease. Atherosclerosis 1999; 147(suppl 1): S11-S16.
80. Grundy SM, Balady GJ, Criqui MH et al. When to start cholesterol-lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. Circulation 1997; 95: 1683-1685.
81. Wood D. De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.